Form 8-K Karyopharm Therapeutics For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
Karyopharm Therapeutics (KPTI) Initiates Selinexor Phase 2 in SIRRT Patients
November 10, 2014 7:22 AM ESTKaryopharm Therapeutics (Nasdaq: KPTI) announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation (SIRRT) that is relapsed after or refractory to chemotherapy. This multi-center study of Selinexor, one of the company's novel, oral Selective Inhibitor of Nuclear Export / SINE compounds, will enroll approximately 50 patients in approximately 35 sites worldwide.
This single arm, open-label, Phase 2 study will... More
Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9c
November 10, 2014 7:21 AM ESTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52).
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
... More